Daniel Sawyer, MD
Internal Medicine · Charlottesville, VANPI 1649348913
Payments from drug & device makers
Across 248 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$954
- Pfizer$646
- Novartis$551
- Novo Nordisk$404
- Lilly USA, LLC$380
- Johnson & Johnson$356
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,71599%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $954 |
| Pfizer | 31 | $646 |
| Novartis | 34 | $551 |
| Novo Nordisk | 17 | $404 |
| Lilly USA, LLC | 21 | $380 |
| Johnson & Johnson | 13 | $356 |
| Merck | 17 | $295 |
| Amarin Pharma, Inc. | 18 | $224 |
| La Jolla Pharmaceutical Company | 10 | $198 |
| Amgen | 10 | $161 |
| AbbVie(2 entities) | 5 | $81 |
| Gilead | 4 | $78 |
| Exact Sciences | 4 | $77 |
| Genentech USA, Inc. | 3 | $54 |
| Bayer | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Vyera Pharmaceuticals, LLC | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Medtronic | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| GSK | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$118
- AIRSUPRA$117
- PREVNAR - 13$101
How this compares
$4,782 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 123 | $137,702 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 22 | $91,226 |
| OzempicSemaglutide | 67 | $72,202 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $59,005 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $57,647 |
| MounjaroTirzepatide | 49 | $50,899 |
| JardianceEmpagliflozin | 24 | $39,784 |
| FarxigaDapagliflozin Propanediol | 32 | $34,653 |
| JanuviaSitagliptin Phosphate | 32 | $34,194 |
| Victoza 3-PakLiraglutide | 12 | $25,476 |
| XareltoRivaroxaban | 15 | $16,610 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $16,319 |
| LinzessLinaclotide | 16 | $14,586 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $8,860 |
| Spiriva HandihalerTiotropium Bromide | 11 | $6,573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadStribild, Genvoya, Biktarvy | $78 | $207,87850 claims |
| PfizerEliquis | $646 | $137,702123 claims |
| Novo NordiskOzempic | $404 | $72,20267 claims |
| Lilly USA, LLCMounjaro | $380 | $50,89949 claims |
| Boehringer IngelheimJardiance | $18 | $39,78424 claims |
| AstraZenecaFarxiga | $954 | $34,65332 claims |
| MerckJanuvia | $295 | $34,19432 claims |
| AbbVieLinzess, Savella, Synthroid | $81 | $20,00066 claims |
| Johnson & JohnsonXarelto | $356 | $16,61015 claims |
| GSKTrelegy Ellipta | $13 | $16,31923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Charlottesville
- James ClarkCharlottesville$16.2M
- Michael DevittCharlottesville$3.5M
- Sue BrownCharlottesville$2.4M
- Jeffrey SturekCharlottesville$156K
- Leroy VaughanRichmond$20.8M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.